AI Rally 2026: Meta and Apple Lead Gains, Recursion Remains High-Risk
TL;DR
Two AI-focused bets—Meta Platforms and Apple—are highlighted as solid 2026 opportunities due to AI-driven monetization and a strong device-cycle backdrop, while Recursion Pharmaceuticals represents a high-risk AI drug-discovery play with no products on the market and increasing competition from larger pharma players.
Want the full story? Read the original reporting
Read on The Motley Fool